Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-1 Antibodies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT03952065
What this trial is testing

IT or IA Infusion of PD1/PDL1/CTLA4 Inhibitors Versus IV for Immunotherapy of Head/Neck Cancers (HNC)

Who this might be right for
Head/Neck Neoplasm
Second Affiliated Hospital of Guangzhou Medical University 200
Early research (Phase 1)Study completedNCT05040932
What this trial is testing

Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy

Who this might be right for
Cancer
Eucure (Beijing) Biopharma Co., Ltd 8
Testing effectiveness (Phase 2)Active Not RecruitingNCT06449209
What this trial is testing

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

Who this might be right for
Extensive-stage Small-cell Lung CancerSmall-cell Lung Cancer
BioNTech SE 110
Testing effectiveness (Phase 2)Study completedNCT05578872
What this trial is testing

ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).

Who this might be right for
Melanoma (Skin)Cutaneous MelanomaAdult Disease+2 more
Anaveon AG 29
Testing effectiveness (Phase 2)UnknownNCT04177875
What this trial is testing

Neoadjuvant Chemoradiotherapy Combined With PD-1 Antibody in Locally Advanced Esophageal Cancer

Who this might be right for
Esophagus Cancer
Tongji Hospital 44
Testing effectiveness (Phase 2)Looking for participantsNCT05751798
What this trial is testing

Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

Who this might be right for
Solid Advanced TumorLymphomaNSCLC (Non-small Cell Lung Cancer)
OSE Immunotherapeutics 41
Large-scale testing (Phase 3)Looking for participantsNCT07010263
What this trial is testing

AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Who this might be right for
Small Cell Lung Cancer
Akeso 560
Large-scale testing (Phase 3)Active Not RecruitingNCT05587374
What this trial is testing

Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)

Who this might be right for
Nasopharyngeal CarcinomaNasopharyngeal Cancer
Sun Yat-sen University 490
Testing effectiveness (Phase 2)Study completedNCT02684461
What this trial is testing

Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel

Who this might be right for
Non Small Cell Lung Cancer
UNC Lineberger Comprehensive Cancer Center 20
Testing effectiveness (Phase 2)WithdrawnNCT04373083
What this trial is testing

Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
Regeneron Pharmaceuticals
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07688291
What this trial is testing

A Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After Failure of Prior ICI Plus Platinum-Based Chemotherapy

Who this might be right for
Esophageal Squamous Carcinoma Cell
Beijing GoBroad Hospital 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07555860
What this trial is testing

Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

Who this might be right for
Nasopharyngeal Carcinoma
Sun Yat-sen University 28
Testing effectiveness (Phase 2)Ended earlyNCT03173950
What this trial is testing

Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers

Who this might be right for
MedulloblastomaEpendymomaPineal Region Tumors+2 more
National Cancer Institute (NCI) 136
Testing effectiveness (Phase 2)UnknownNCT03925090
What this trial is testing

Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients

Who this might be right for
Nasopharyngeal Carcinoma
Sun Yat-sen University 150
Early research (Phase 1)Active Not RecruitingNCT05007782
What this trial is testing

Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
Gilead Sciences 304
Testing effectiveness (Phase 2)Looking for participantsNCT03591276
What this trial is testing

Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Shaare Zedek Medical Center 15
Early research (Phase 1)Study completedNCT03203876
What this trial is testing

A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors

Who this might be right for
Advanced Cancer
Bristol-Myers Squibb 10
Early research (Phase 1)Temporarily pausedNCT07395258
What this trial is testing

Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

Who this might be right for
Solid Tumors
Boehringer Ingelheim 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT03607890
What this trial is testing

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Who this might be right for
Refractory MSI - H Solid Tumors Prior of PD-(L) 1 TherapyMSI-H Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 38
Testing effectiveness (Phase 2)Active Not RecruitingNCT03680508
What this trial is testing

TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer

Who this might be right for
Adult Primary Liver CancerAdvanced Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver Cancer
University of Hawaii 42
Next Page